13 research outputs found

    Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich Glycoproteins

    Get PDF
    Selenof (15-kDa selenoprotein; Sep15) is an endoplasmic reticulum (ER)-resident thioredoxin-like oxidoreductase that occurs in a complex with UDPglucose: glycoprotein glucosyltransferase. We found that Selenof deficiency in mice leads to elevated levels of non-functional circulating plasma immunoglobulins and increased secretion of IgM during in vitro splenic B cell differentiation. However, Selenof knockout animals show neither enhanced bacterial killing capacity nor antigen-induced systemic IgM activity, suggesting that excess immunoglobulins are not functional. In addition, ER-to-Golgi transport of a target glycoprotein was delayed in Selenof knockout embryonic fibroblasts, and proteomic analyses revealed that Selenof deficiency is primarily associated with antigen presentation and ER-to-Golgi transport. Together, the data suggest that Selenof functions as a gatekeeper of immunoglobulins and, likely, other client proteins that exit the ER, thereby supporting redox quality control of these proteins

    Transfected HEK293 Cells Expressing Functional Recombinant Intercellular Adhesion Molecule 1 (ICAM-1) – A Receptor Associated with Severe Plasmodium falciparum Malaria

    Get PDF
    Intercellular adhesion molecule 1 (ICAM-1) is a membrane-bound glycoprotein expressed on endothelial cells and cells of the immune system. Human ICAM-1 mediates adhesion and migration of leucocytes, and is implicated in inflammatory pathologies, autoimmune diseases and in many cancer processes. Additionally, ICAM-1 acts as receptor for pathogens like human rhinovirus and Plasmodium falciparum malaria parasites. A group of related P. falciparum erythrocyte membrane protein 1 (PfEMP1) domains, the DBLβ, mediates ICAM-1 binding of P. falciparum-infected erythrocytes. This ICAM‑1-binding phenotype has been suggested to be involved in the development of cerebral malaria. However, more studies identifying cross-reactive antibody and ICAM-1-binding epitopes and the establishment of a clinical link between DBLβ expression and e.g. cerebral malaria are needed before the DBLβ domains can be put forward as vaccine candidates and go into clinical trials. Such studies require availability of functional recombinant ICAM-1 in large quantities. In this study, we compared recombinant ICAM-1 expressed in HEK293 and COS-7 cells with mouse myeloma NS0 ICAM-1 purchased from a commercial vendor in terms of protein purity, yield, fold, ability to bind DBLβ, and relative cost. We present a HEK293 cell-based, high-yield expression and purification scheme for producing inexpensive, functional ICAM‑1. ICAM-1 expressed in HEK293 is applicable to malaria research and can also be useful in other research fields

    Binding of the malaria PfEMP1 antigen DBLβ3_D4 to ICAM-1-Fc.

    No full text
    <p>Concentration-dependent binding of recombinant <i>P. falciparum</i> 3D7 PFD1235w DBLβ3_D4 to ICAM-1-Fc<sub>HEK239,</sub> ICAM-1-Fc<sub>COS-7</sub> and ICAM-1-Fc<sub>NS0</sub> (R&D Systems) by ELISA. The binding of DBLβ3_D4 to ICAM-1-Fc<sub>HEK239</sub> was repeated in three independent experiments (mean and standard deviation shown) while the assay using ICAM-1-Fc<sub>COS-7</sub> and ICAM-1-Fc<sub>NS0</sub> (R&D Systems) was done one time each.</p

    Comparison of ICAM-1-Fc by Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

    No full text
    <p>SDS-PAGE gel electrophoresis of 5 µg of ICAM-1-Fc expressed in HEK293 cells, COS-7 cells or in mouse myeloma NS0 (R&D Systems) cells. 5 µl protein marker (M) was loaded onto the gel. Samples were reduced using DTT (+) or non-reduced (−). Arrows indicate ICAM-1-Fc bands.</p

    Purification of ICAM1-Fc expressed by HEK293 cells.

    No full text
    <p>Data from exp. #1 is shown here as an example of purification of ICAM-1-Fc<sub>HEK293</sub>. (<b>A</b>) Dot blot showing 2 µl of cell supernatant at day of harvest, 2 µl diafiltrated supernatant (column input) and 2 µl column run-through. 1.8 µg and two ten-fold dilutions hereof of the eluted ICAM-1-Fc was dotted onto the membrane. ICAM-1-Fc was detected using HRP-conjugated anti-human IgG antibody. (<b>B</b>) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel electrophoresis of 5 µl protein marker (lane 1), 10 µl column input (lane 2), 10 µl column run-through (lane 3) and 9 µg eluted ICAM-1-Fc (lane 4+5). Samples were reduced using DTT (+) or non-reduced (−). Arrows indicate ICAM-1-Fc bands.</p

    Reactivity of monoclonal ICAM antibodies.

    No full text
    <p>The reactivity of seven anti-human ICAM-1 specific monoclonal antibodies (clones 15.2, RR1/1, 84H10, LB2, BBIG-I1, 8.4A6 and My13) against ICAM-1-Fc expressed in HEK293, COS-7 or mouse myeloma NS0 (R&D Systems) cells were tested using ELISA. One CD36 specific monoclonal antibody (clone FA6.152) was included as negative control. Data shown are the mean reactivity (three independent experiments) of the antibodies to ICAM-1. Errors indicate S.D.</p

    Role of Selenof as a Gatekeeper of Secreted Disulfide-Rich Glycoproteins

    Get PDF
    Selenof (15-kDa selenoprotein; Sep15) is an endoplasmic reticulum (ER)-resident thioredoxin-like oxidoreductase that occurs in a complex with UDPglucose: glycoprotein glucosyltransferase. We found that Selenof deficiency in mice leads to elevated levels of non-functional circulating plasma immunoglobulins and increased secretion of IgM during in vitro splenic B cell differentiation. However, Selenof knockout animals show neither enhanced bacterial killing capacity nor antigen-induced systemic IgM activity, suggesting that excess immunoglobulins are not functional. In addition, ER-to-Golgi transport of a target glycoprotein was delayed in Selenof knockout embryonic fibroblasts, and proteomic analyses revealed that Selenof deficiency is primarily associated with antigen presentation and ER-to-Golgi transport. Together, the data suggest that Selenof functions as a gatekeeper of immunoglobulins and, likely, other client proteins that exit the ER, thereby supporting redox quality control of these proteins

    Shedding of Hepatitis C Virus in Semen of Human Immunodeficiency Virus-Infected Men.

    No full text
    Background.  The epidemic of sexually transmitted hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-infected men who have sex with men (MSM) has been documented for over a decade. Despite this, there is no consensus as to the risk factors for sexual acquisition of HCV in these men. Methods.  We obtained paired semen and blood samples at 2-week intervals from HIV-infected MSM with recent and chronic HCV infection and quantified HCV in semen. Results.  Hepatitis C virus was quantified in 59 semen specimens from 33 men. Hepatitis C virus was shed in 16 (27%) of semen specimens from 11 (33%) of the men. Median HCV viral load (VL) in semen was 1.49 log10 IU/mL. Hepatitis C virus VL in blood was significantly higher at the time of HCV shedding in semen than when HCV shedding in semen was not detected (P = .002). Furthermore, there was a significant correlation between the HCV VL in blood and semen overall (rs = 0.41; P = .001), and in the subgroup with recent HCV infection (rs = 0.37; P = .02), but not in the subgroup with chronic HCV infection (rs = 0.34; P = .1). Conclusions.  One third of HIV-infected MSM coinfected with HCV shed HCV into their semen. Based on the HCV VL in semen in this study, an average ejaculate would deliver up to 6630 IU of virus into the rectum of the receptive partner. Therefore, our data strongly support that condoms should be used during anal intercourse among MSM to prevent transmission of HCV
    corecore